Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver.

Romero-Gutiérrez, Marta; Tercero, María Abanades; Martín, Juan Ruiz; Limo, Juan Diego Castro; Varasa, Tomás Artaza; Frutos, Concepción González de; Pérez, Gema; Ruano, Juan; Moreno, Ana Zaida Gómez; Rodríguez, Rafael Gómez

doi:10.17235/reed.2019.6180/2018

Cited by 2 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We report on a single centre study with 249 patients who underwent liver resection for NC-HCC. As only a few studies selectively address the entity of NC-HCC [ 21 , 22 , 23 , 24 , 25 , 26 ] this is, to the best of our knowledge, the largest surgical NC-HCC collective in the Western world. Our aim was a structured evaluation of our cohort and the determination of prognostic factors for OS and intrahepatic RFS.…”

Section: Discussionmentioning

confidence: 99%

Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study

Penzkofer

Mittler

Heinrich

et al. 2022

JCM

View full text Add to dashboard Cite

Liver cirrhosis is the most common risk factor for the development of hepatocellular carcinoma (HCC). However, 10 to 15% of all HCC arise in a non-cirrhotic liver. Few reliable data exist on outcome after liver resection in a non-cirrhotic liver. The aim of this single-centre study was to evaluate the outcome of resection for HCC in non-cirrhotic liver (NC-HCC) and to determine prognostic factors for overall (OS) and intrahepatic recurrence-free (RFS) survival. From 2008 to 2020, a total of 249 patients were enrolled in this retrospective study. Primary outcome was OS and RFS. Radiological and pathological findings, such as tumour size, number of nodules, Tumour-, Nodes-, Metastases- (TNM) classification and vascular invasion as well as extent of surgical resection and laboratory liver function were collected. Here, 249 patients underwent liver resection for NC-HCC. In this case, 50% of patients underwent major liver resection, perioperative mortality was 6.4%. Median OS was 35.4 months (range 1–151 months), median RFS was 10.5 months (range 1–128 moths). Tumour diameter greater than three centimetres, multifocal tumour disease, vascular invasion, preoperative low albumin and increased alpha-fetoprotein (AFP) values were associated with significantly worse OS. Our study shows that resection for NC-HCC is an acceptable treatment approach with comparatively good outcome even in extensive tumours.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study

Penzkofer

Mittler

Heinrich

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…However, in clinical subgroups, significant differences were not found between patients with/without pretransplant RFA. We consider these results in traditional clinical subgroups were not in conflict with previous studies [ 38 , 39 ], for CTC result is a novel biomarker to evaluate the risk of recurrence and may be a complementary biomarker of traditional clinical indicators to pretransplant RFA in HCC patients. It can be applied to the guidance for the downstaging treatment before LT [ 40 ].…”

Section: Discussionmentioning

confidence: 67%

Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma

Chen

Wang

Chen

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Introduction. It is of great significance to confirm reliable indicators for the guidance of pretransplant radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). In this study, we aim to investigate whether circulating tumor cell (CTC) status is a clinical indicator for RFA before liver transplantation (LT) in HCC patients. Method. CTC analyses were measured in 79 HCC patients. Clinical outcomes including progression-free (PFS) and overall survival (OS) were compared and analyzed between patients with and without pretransplant RFA. Result. Forty-two patients were detected as CTC-positive and 18 patients received pretransplant RFA. Recurrence was correlated with CTC count ( P = 0.024 ), tumor number ( P = 0.035 ), liver cirrhosis ( P = 0.001 ), Milan criteria ( P = 0.003 ), and University of California San Francisco (UCSF) criteria ( P = 0.001 ). Kaplan–Meier analysis revealed that patients with CTC-positive had a lower PFS rate ( P = 0.0257 ). For CTC-positive patients, the PFS rate of the pretransplant RFA group was significantly higher than the non-pretransplant RFA group (100% vs. 46.7%, P = 0.0236 ). For CTC-negative patients, both PFS rate and OS rate were similar and without significant differences. In multivariate analysis, pretransplant RFA was the independent factor for PFS ( P = 0.025 ). Conclusion. Pretransplant CTC status can guide the administration of pretransplant RFA in HCC patients which can improve PFS in CTC-positive HCC patients.

show abstract

Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver.

Cited by 2 publications

References 38 publications

Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study

Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver—A Single Centre Study

Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma

Contact Info

Product

Resources

About